Banoub Rita, Alalade Emmanuel, Bryant Jason, Winch Peter, Tobias And Joseph D
Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital and The Ohio State University, Columbus, OH.
J Pediatr Pharmacol Ther. 2023;28(4):374-379. doi: 10.5863/1551-6776-28.4.374. Epub 2023 Aug 9.
Sugammadex is a novel agent for the reversal of neuromuscular blockade; it acts by encapsulating -rocuronium or vecuronium, eliminating the active compound from the circulation, thereby providing rapid and complete recovery even with profound or complete neuromuscular blockade. Clinical advantages, including reduced incidence of residual blockade, decreased nausea and vomiting, decreased dry mouth, less change in heart rate, and reduced pulmonary complications, have been demonstrated when comparing sugammadex to conventional agents, such as neostigmine, that inhibit acetylcholinesterase. Although generally safe and effective, anaphylactoid and allergic reactions have been reported with sugammadex. The potential for hypersensitivity reactions with sugammadex and previous reports from the literature, as well as diagnostic and treatment strategies, are presented in 3 pediatric cases.
舒更葡糖钠是一种用于逆转神经肌肉阻滞的新型药物;它通过包裹罗库溴铵或维库溴铵起作用,从循环中清除活性化合物,从而即使在深度或完全神经肌肉阻滞的情况下也能实现快速且完全的恢复。与新斯的明等抑制乙酰胆碱酯酶的传统药物相比,舒更葡糖钠已显示出临床优势,包括残余阻滞发生率降低、恶心和呕吐减少、口干减轻、心率变化较小以及肺部并发症减少。尽管舒更葡糖钠总体上安全有效,但已有关于其过敏样和过敏反应的报道。本文通过3例儿科病例介绍了舒更葡糖钠发生超敏反应的可能性、既往文献报道以及诊断和治疗策略。